1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>China

AstraZeneca VP Detlev Biniszkiewicz On Building An Oncology Strategy In China And Asia

 
• By Joshua Berlin

Fresh off a global deal to in-license a novel oncology molecule discovered in China, the head of strategy for AZ’s Oncology Innovative Medicine Unit speaks with PharmAsia News during the JP Morgan Healthcare Conference about how AstraZeneca’s strategy in Asia differs from its peers.

SAN FRANCISCO – AstraZeneca PLC, like many of its peers, is looking to Asia, particularly China, for new growth opportunities as it wades through the patent cliff, European austerity measures and a plethora of challenges to the bottom line. The U.K. company, which ranks second behind Pfizer Inc. in China’s highly fragmented pharmaceutical market, has focused on a mix of branded generics and innovative medicines to capture the opportunity.

In December, for instance, AZ bought a Chinese generics injectable manufacturer – just one day after it announced layoffs to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Asia

Australia Looks To Modernize Human Tissue Laws, Improving Access For Researchers

 
• By Eliza Slawther

Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.

China NMPA Lays Out Regulatory Priorities At DIA

 
• By Xu Hu

At this year’s DIA China meeting, the national regulator updated its policy focus areas for this year, including clinical trial data protection and pilot projects to shorten IND approval times.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.